Abstract:Alport syndrome (AS) is a hereditary kidney disease associated with proteinuria, hematuria and progressive kidney failure. It is characterized by a defective glomerular basement membrane caused by mutations in type IV collagen genes COL4A3/A4/A5 which result in defective type IV collagen α3, α4, or α5 chains, respectively. Alport syndrome has three different patterns of inheritance: X-linked, autosomal and digenic. In a study of CKD of unknown etiology type IV collagen gene mutations accounted for the majority of the cases of hereditary glomerulopathies which suggests that AS is often underrecognized. The natural history and prognosis in patients with AS is variable and is determined by genetics and environmental factors. At present, no preventive or curative therapies exist for AS. Current treatment includes the use of renin-angiotensin-aldosterone system inhibitors which slow progression of kidney disease and prolong life expectancy. Ramipril was found in retrospective studies to delay the onset of ESKD and was recently demonstrated to be safe and effective in children and adolescents, supporting that early initiation of Renin Angiotensin Aldosterone System (RAAS) blockade is very important. Mineralocorticoid receptor blockers might be favorable for patients who develop "aldosterone breakthrough." While the DAPA-CKD trial suggests a beneficial effect of SGLT2 inhibitors in CKD of non-metabolic origin, only a handful of patients had Alport in this cohort, and therefore conclusions can't be extrapolated for the treatment of AS with SGLT2 inhibitors. Advances in our understanding on the pathogenesis of Alport syndrome has culminated in the development of innovative therapeutic approaches that are currently under investigation. We will provide a brief overview of novel therapeutic targets to prevent progression of kidney disease in AS. Our review will include bardoxolone methyl, an oral NRf2 activator; lademirsen, an anti-miRNA-21 molecule; sparsentan, dual endothelin type A receptor (ETAR) and angiotensin 1 receptor inhibitor; atrasentan, oral selective ETAR inhibitor; lipid-modifying agents, including cholesterol efflux transporter ATP-binding cassette A1 (ABCA1) inducers, discoidin domain receptor 1 (DDR1) inhibitors and osteopontin blocking agents; the antimalarial drug hydroxychloroquine; the antiglycemic drug metformin and the active vitamin D analog paricalcitol. Future genomic therapeutic strategies such as chaperone therapy, genome editing and stem cell therapy will also be discussed.

Pharmacological approach and diagnosis for Alport syndrome

Novel Therapies for Alport Syndrome

Exploration of Gene Therapy for Alport Syndrome

Alport Syndrome: a Unified Classification of Genetic Disorders of Collagen IV Alpha 345: a Position Paper of the Alport Syndrome Classification Working Group

Genotype-Phenotype Correlations for Pathogenic COL4A3–COL4A5 Variants in X-Linked, Autosomal Recessive, and Autosomal Dominant Alport Syndrome

Pathological diagnosis of Alport syndrome

Four novel mutations identified in the COL4A3, COL4A4 and COL4A5 genes in 10 families with Alport syndrome

Novel Mutations In Col4a3, Col4a4, And Col4a5 In Chinese Patients With Alport Syndrome

Synergistic Toxicity of Compound Heterozygous Mutations in the COL4A3 Gene Causes End-Stage Renal Disease in A Large Family of Alport Syndrome

Dissecting the genotype-phenotype correlation of <i>COL4A5</i> gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome

iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome

Establishment of Microrna, Transcript and Protein Regulatory Networks in Alport Syndrome Induced Pluripotent Stem Cells

Renal, Auricular, and Ocular Outcomes of Alport Syndrome and Their Current Management

Advances and Unmet Needs in Genetic, Basic and Clinical Science in Alport Syndrome: Report from the 2015 International Workshop on Alport Syndrome.

Adverse effects of Alport syndrome-related Gly missense mutations on collagen type IV: Insights from molecular simulations and experiments

Alport syndrome: Expanding diagnosis and treatment

Genetic diagnosis of Alport syndrome in 16 Chinese families

Identification of a Novel COL4A5 Mutation in a Chinese Family with X-linked Alport Syndrome Using Exome Sequencing.

A mouse model for X-linked Alport syndrome induced by Del-ATGG in the Col4a5 gene

Quantitative Analysis of Type IV Collagen Subchains in the Glomerular Basement Membrane of Patients with Alport Syndrome with Confocal Microscopy.

Detection of COL4A5 Gene Mutations in Chinese Patients with Alport's Syndrome